Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2008 Jun 19;26(26):3209-22. doi: 10.1016/j.vaccine.2008.03.093. Epub 2008 Apr 21.

Safety of MF59 adjuvant.

Author information

1
Novartis Vaccines and Diagnostics, Marburg, Germany. viola.schultze@novartis.com

Abstract

The need to enhance the immunogenicity of purified subunit antigens has prompted the development of new adjuvants. The adjuvant emulsion MF59 has been tested in animals in combination with different antigens and finally evaluated in humans. It was licensed after the successful outcome of preclinical and clinical testing. This paper summarizes the main characteristics of the MF59 adjuvant, including animal testing, clinical experience with various vaccines, and information from current postmarketing surveillance data. This review supports the hypothesis that MF59 is a safe adjuvant for human use.

PMID:
18462843
DOI:
10.1016/j.vaccine.2008.03.093
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center